🇺🇸

US SEC Filing Intelligence

· daily

US Earnings Financial Results SEC Filings — March 11, 2026

Across the 50 filings in the Financial Results & Earnings stream (46 new), results are predominantly mixed with 22 positive, 15 negative, and 13 neutral sentiments, reflecting resilient growth in cloud/tech (e.g., Oracle +22% YoY revenue to $17.2B, Marvell +42% to $8.2B) and retail giants (Costco +9.3% Q2 revenue to $69.6B) offset by sharp declines in AI/software (C3.ai -46% Q3 revenue to $53.3M) and consumer staples (Campbell's -4.5%, Target -1.7% FY sales). Period-over-period trends show average revenue growth of +15% YoY in top performers (n=18) but -10% in laggards (n=12), with margin compression averaging -100bps in 14 companies due to higher OpEx/R&D; banks expanded assets +30% avg (n=5) but NIM mixed (improving in CNB/LCNB, declining elsewhere). Biotechs/pharmas (n=12) narrowed net losses 20-77% via cost cuts, while SPACs (n=4) saw trust redemptions -70-92%. Capital allocation favors dividends/buybacks in stables (Costco EPS +14%, Oil-Dri dividends +24%), acquisitions drive growth (AeroVironment +143% revenue). Portfolio implications: overweight tech/cloud/defense outperformers, underweight high-burn AI/biotechs; watch bank NIM and biotech cash burns for Q1 2026 catalysts amid 2026-03 period focus.

50 high priority 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — March 11, 2026

Across 30 DEF 14A proxy statements, 2025 financial performance was predominantly strong with 18/30 filings highlighting YoY revenue growth averaging ~7% (e.g., PNC +7%, Levi +7% organic, Genpact +6.6%, Graco +6%), EPS expansion (Ryder +8.4%, Northern Trust +17%, C&F +38%), and robust capital returns including $3.9B shareholder payouts at PNC and $2.4B buybacks at MSCI. Positive sentiment dominates (14/30 filings), driven by innovation, M&A (PNC's FirstBank adding $26B assets post-2025), and expansions (Life Time's 10 new clubs, JNJ's Orthopaedics separation), while mixed/neutral tones appear in flat revenue cases like Valmont (~$4.1B unchanged YoY) and incentive declines (Triumph non-equity -2% YoY). Portfolio-level trends show financials leading with avg net income +20% YoY (PNC +18%, C&F +36%), industrials mixed (Graco sales +6% but TSR flat), and high insider alignment via equity-heavy comp (Triumph CEO stock awards $2.81M driving +31% total pay). Forward-looking catalysts cluster in April-May 2026 AGMs for comp votes (say-on-pay >90% historical approvals like AMETEK 95% avg), auditor ratifications, and director elections amid board refreshes (JNJ adding Pinto/Morikis, Levi chair transition). Capital allocation favors dividends (+5-8% at Smurfit/Graco) and buybacks (Life Time $500M new program), signaling confidence; however, controlled companies (Biglari, Travelzoo) exempt from some governance norms raise minor flags. Overall, bullish for growth names pre-AGM, with watch for say-on-pay risks in mixed comp filers.

30 high priority 30 total filings
· daily

US Executive Officer Management Changes SEC — March 11, 2026

Across 36 filings in the USA Executive & Director Changes stream (March 11, 2026), executive turnover dominates with 18 departures/resignations (e.g., CFOs at Lattice, Bridger, Peloton; Group Presidents at onsemi; CLO at Biogen), mostly neutral sentiment and not due to disagreements, signaling routine transitions amid sector shifts. Positive appointments (9 cases, e.g., experienced CFOs at Navitas/Bridger, Chairman at Mainz Biomed pivoting to Quantum Cyber) outnumber negatives, with compensation enhancements (e.g., PSUs extensions at Target Hospitality, salary hikes at Farmer Mac) in 7 filings indicating retention focus. Limited period-over-period financials show outliers like Tilly's Q4 FY2025 sales +5.3% YoY (comp sales +10.1%) vs FY -2.8%, Atlassian's cloud revenue +25% despite 10% layoffs, and Blue Bird's equity plan expansion +17.3% shares. No widespread insider trading but high CFO churn (5 cases) raises conviction questions; forward-looking catalysts cluster in Q2 2026 (EGMs, annual meetings). Portfolio-level: Neutral-to-positive board refreshments in semis/AI/crypto, potential alpha from undervalued turnarounds but risks from undisclosed details in 5 filings. Overall, low materiality average (5.5/10) suggests limited immediate volatility but monitor transitions for operational hiccups.

36 high priority 36 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — March 11, 2026

Across 32 filings in the USA Corporate Distress & Bankruptcy stream, key themes include Nasdaq minimum bid price non-compliance (GameSquare, VYNE Therapeutics, SmartKem) granting extensions to Sep 2026, signaling persistent stock price weakness and delisting risks; dilutive financings via convertible notes/promissory notes (CERO Therapeutics $937.5k note at $0.05 conversion, SunPower $10M debenture at $2.50/share, Liberty Star $110k note); defensive shareholder rights plans (Starz at 17.5% trigger, Enzon extension); and liquidity support through credit facilities/extensions (Consolidated Edison $3.5B revolver, Advantage Solutions ABL amendment). Positive M&A offsets distress with Cintas/UniFirst $5.5B deal at 8.0x EBITDA (Cintas Q3 rev +8.9% YoY to $2.84B), Sphere 3D/Cathedra bitcoin mining merger (53MW capacity), Aureus/Powerus drone merger ($50M investment). Limited period trends show revenue growth outliers (Cintas +8.9% YoY organic +8.2%), but no widespread margin compression or YoY declines; neutral/mixed sentiment dominates (22/32), with 6 positive. Implications: Heightened short-term volatility from compliance deadlines, dilution risks eroding equity value, but M&A catalysts offer turnaround potential in services/tech.

32 high priority 32 total filings
· daily

US SEC Trading Suspension Halt Orders — March 11, 2026

Three small-cap companies—GameSquare Holdings, VYNE Therapeutics, and SmartKem—face Nasdaq minimum bid price delisting risks after closing bid prices below $1.00 for 30+ consecutive business days, with extensions granted to GameSquare and VYNE until September 7, 2026, and an initial 180-day period for SmartKem until September 1, 2026. Persistent sub-$1 bid prices since September 2025 for GameSquare and VYNE indicate QoQ/QoY stock price deterioration over 6 months, while SmartKem's issue spans January 21 to March 4, 2026. All exhibit mixed to negative sentiment due to no compliance assurances and potential reverse stock splits, with high materiality (8-10/10). No period-over-period financial trends, insider activity, capital allocation, or M&A details reported, focusing risks on regulatory halts. Portfolio-level pattern: 3/3 companies meet other listing criteria except bid price, highlighting small-cap liquidity challenges; implications include heightened delisting volatility and short-term trading opportunities ahead of reverse split catalysts.

3 high priority 3 total filings
· daily

US Corporate Board Director Changes SEC Filings — March 11, 2026

Across 36 SEC filings on USA Board Room Changes from March 11, 2026, a dominant theme is elevated C-suite and board turnover, with 18 departures/resignations/retirements (e.g., CFOs at Peloton, Bridger, Lattice; Presidents at ON Semi, Rayonier) versus 12 new appointments, signaling potential leadership transitions amid sector pressures. Neutral sentiment prevails in 70% of filings, with positive tones on experienced hires in AI/cyber (Mainz Biomed, Navitas, Spire) and mixed in cases like Atlassian's 10% workforce cut despite 25%+ cloud revenue growth. Period-over-period financial trends are sparse but highlight outliers: Tilly's Q4 FY2025 net sales +5.3% YoY to $155.1M with first profitable Q4 since FY2021 ($2.9M NI vs -$13.7M prior), contrasting FY2025 net loss improvement to -$17.5M from -$46.2M. No widespread insider trading data, but capital allocation via incentive plans (e.g., PSIX Phantom Units, Lifeway deferred cash) indicates retention focus. Portfolio-level pattern: Tech/semi sector sees 6/10 filings with finance/legal exits (Lattice CAO, ON Semi President), potentially bearish short-term but bullish on replacements like Navitas CFO. Upcoming catalysts include Mainz EGM (April 2026) and multiple 2026 AGMs.

36 high priority 36 total filings
· daily

US Merger & Acquisition SEC Filings — March 11, 2026

The 9 filings reveal a vibrant SPAC-driven M&A landscape, with 6/9 involving SPACs at various stages: IPO consummation (GalaxyEdge $100M), shareholder approvals (TLGY 97% vote, 6.7% redemptions), extensions (Future Vision II to April 13), clarifications (Pelican no 1% excise tax), terminations (Yotta), and underwriting amendments (Quantumsphere/Quartzsea at 4% deferred commissions). Sonida Senior Living's $1.8B merger completion with CNL Healthcare stands out, delivering 62% Normalized FFO accretion, 153 communities, and $930M debt financing for a $3.3B entity. Joby's $30.75M property loan supports eVTOL expansion. No explicit YoY/QoQ financial trends reported, but low TLGY redemptions (6.7% vs typical 20-50% in SPACs) and Sonida's 50/50 ownership split signal strong deal momentum. Portfolio-level patterns show 4 positive, 1 negative, 4 neutral sentiments; active capital raises/extensions indicate persistent M&A pursuit despite headwinds. Implications: heightened takeover activity favors operators like Sonida, while SPACs offer merger catalysts.

9 high priority 9 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 11, 2026

Overnight SEC filings reveal mixed financial performances across sectors, with standout revenue growth in tech/AI (Oracle +22% YoY to $17.2B, TSS +66% YoY to $245.7M, AeroVironment +143% YoY to $408M Q3) offset by sharp declines (C3.ai -46% YoY to $53.3M, Target Hospitality -17% YoY to $320.6M) and margin compressions (Smith Douglas gross margin -440 bps to 21.8%). SPAC activity dominates with merger approvals (TLGY 97% quorum, near-100% approval for StablecoinX), terminations (Yotta), and IPO filings (Pono Capital $150M, BEST SPAC II $100M), signaling ongoing consolidation. M&A momentum builds via Cintas' $5.5B UniFirst acquisition (8x EBITDA, EPS accretive) and Contango ORE's Dolly Varden deal (proxy support from ISS). Capital returns strengthen (ICL $232M dividends +3.1% yield, News Corp $1B buyback, Pangaea $0.05/share dividend + $1M repurchases), while guidance varies (TSS $20-22M EBITDA 2026, Serve Robotics $26M revenue 2026). Portfolio trends show 12/20 quarterly reporters with YoY revenue growth averaging +45% but net losses in 8/20 due to impairments/expenses; watch Nasdaq compliance (GameSquare extension to Sep 2026) and clinical catalysts.

28 high priority 22 medium 50 total filings
· daily

Biotech Small-Cap Approvals — March 10, 2026

Nine small-cap biotech firms—primarily Indian generics players—received FDA ANDA approvals for original generic drugs from March 4-6, 2026, all under standard review with no special designations or specified indications. This tight cluster signals routine pipeline execution and portfolio expansion but lacks NME innovation or priority status for high-impact growth. Neutral investment implications dominate, with competition and pricing pressures offsetting modest market entry opportunities.

9 total filings
· daily

Big Pharma Approvals — March 10, 2026

Big Pharma approvals were predominantly neutral (3/4 records) for established immunology drugs from Pfizer and AbbVie, signaling pipeline stability with no risks or opportunities flagged. Janssen Biotech's sole bullish signal—FDA supplemental approval for TECVAYLI (teclistamab-cqyv) on 2026-03-05 under Priority Review with Orphan Drug designation—offers potential revenue upside via premium pricing and label expansion. Investors should prioritize Janssen monitoring amid otherwise quiet activity.

4 total filings
· daily

Orphan Drug Approvals — March 10, 2026

Janssen Biotech's TECVAYLI received FDA supplemental approval under Priority Review with Orphan Drug designation, a bullish signal for revenue via premium pricing and potential efficacy expansion despite unspecified indication. AbbVie's RISANKIZUMAB-RZAA was neutral with no risks or opportunities identified. Period shows selective bullish divergence in orphan drug approvals, favoring Janssen in biotech oncology/immunology.

2 total filings
· daily

New Drug Approvals (Original) — March 10, 2026

FDA issued 9 original ANDA approvals from March 4-6, 2026, all under standard review priority with no special designations, signaling routine generic pipeline execution. Beneficiaries include Lupin Ltd, Mylan, and smaller sponsors like Micro Labs, Laurus, and others, primarily in commoditized therapeutics (e.g., antidepressants, NSAIDs, antipsychotics). Neutral overall: supports steady generic revenue but amplifies competition and pricing risks without innovative upside.

9 total filings
· daily

Federal IT & Cybersecurity Contracts — March 10, 2026

A single $179M firm-fixed-price IT contract awarded to IBM by DHS/FEMA underscores sustained federal demand for computer systems design in emergency mitigation, with 70% ($125M) already outlayed for immediate revenue visibility through mid-2026. This bridge award bolsters IBM's federal backlog but highlights execution risks from cost overruns and post-2026 recompete. Investors should prioritize IBM's federal IT exposure amid concentrated spending in cybersecurity-adjacent services.

1 total filings
· daily

Significant Contract Modifications ($10M+) — March 10, 2026

IBM secured a $179M firm-fixed-price delivery order from DHS/FEMA for IT systems design, with 70% ($125M) already outlayed, providing strong near-term revenue visibility through mid-2026. This bridge contract signals bullish momentum for IBM's government IT segment amid steady federal mitigation spending. Investors should monitor for follow-on awards as the remaining $54M obligation nears completion.

1 total filings
· daily

Contract Option Exercises — March 10, 2026

IBM secured a $179M firm-fixed-price DHS/FEMA contract for IT systems design, with 70% ($125M) already outlayed, providing strong multi-year revenue visibility through mid-2026. This bridge award signals bullish momentum for IBM's federal IT exposure amid full commitment of base + options. Investors should monitor ~$54M remaining obligation and potential follow-ons, tempered by cost overrun risks in fixed-price structure.

1 total filings
· daily

High-Value Federal Grants ($5M+) — March 10, 2026

IBM secured a $179M DHS/FEMA bridge contract for IT systems design, with 70% ($125M) already outlayed, signaling strong execution and multi-year revenue through mid-2026. This fully committed firm-fixed-price award underscores demand for federal mitigation IT support amid disaster preparedness priorities. Remaining $54M obligation offers near-term cash flow visibility, though bridge nature flags potential post-2026 competition.

1 total filings